SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : 2026 TeoTwawKi ... 2032 Darkest Interregnum -- Ignore unavailable to you. Want to Upgrade?

To: THE ANT who wrote (198031)4/9/2023 10:22:47 AM
From: Julius Wong  Read Replies (2) | Respond to of 217689
 
Sarepta Therapeutics ( SRPT) shares increased more than 1% after Citi initiated coverage with a Buy recommendation, citing a compelling setup ahead of an FDA advisory committee meeting for its gene therapy candidate SRP-9001. Analyst Neena Bitritto forecasts a $30-$40/share gain in the event of a positive AdCom vote and a low double digit/share downside.



To: THE ANT who wrote (198031)4/10/2023 9:02:59 PM
From: TobagoJack  Read Replies (1) | Respond to of 217689
 
on it, thank you for the heads-up!
always good for a wager :0)

subscribe to real vision / Raoul Pal



To: THE ANT who wrote (198031)6/21/2024 8:26:36 AM
From: Julius Wong  Read Replies (1) | Respond to of 217689
 


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News